Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CelLBxHealthFRA:DWV +3.23% PB Ratio is 4.00 as of Jul. 16, 2026, which is 6% above its 10-year median of 3.76. The stock has 6 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, CelLBxHealth ranks worse than 54.87% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-16), CelLBxHealth's share price is €0.016. CelLBxHealth's Book Value per Share for the quarter that ended in Jun. 2026 was €0.00. Hence, CelLBxHealth's PB Ratio of today is 4.00.
Warning Sign:
CelLBxHealth PLC stock PB Ratio (=3.38) is close to 3-year high of 3.58.
The historical rank and industry rank for CelLBxHealth's PB Ratio or its related term are showing as below:
FRA:DWV'
s PB Ratio Range Over the Past 10 Years
Min: 0.18 Med: 3.76 Max: 8.6
Current: 3.38
During the past 13 years, CelLBxHealth's highest PB Ratio was 8.60. The lowest was 0.18. And the median was 3.76.
FRA:DWV's PB Ratio is ranked worse than 54.87% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.03
vs FRA:DWV: 3.38
During the past 12 months, CelLBxHealth's average Book Value Per Share Growth Rate was -88.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -66.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -43.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -16.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CelLBxHealth was 152.80% per year. The lowest was -66.00% per year. And the median was -4.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CelLBxHealth PB Ratio Related Terms
CelLBxHealth PB Ratio Historical Data
* Premium members only.
The historical data trend for CelLBxHealth's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, CelLBxHealth's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CelLBxHealth PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, CelLBxHealth's PB Ratio distribution charts can be found below:
* The bar in red indicates where CelLBxHealth's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
CelLBxHealth's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CelLBxHealth (FRA:DWV) has a PB Ratio of 4.00 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CelLBxHealth and its competitors. This is near median its historical median of 3.76. Over the past decade, CelLBxHealth's PB Ratio has ranged from 0.18 to 8.60. According to the industry distribution chart, CelLBxHealth ranks #107 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 54.9%.
Is CelLBxHealth's PB Ratio too high?
CelLBxHealth's current PB Ratio of 4.00 is near median its 10-year median of 3.76. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 8.60. The Medical Diagnostics & Research industry median PB Ratio is 2.03. CelLBxHealth's value of 4.00 is 97% above this industry median. Based on the distribution chart, CelLBxHealth ranks #107 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does CelLBxHealth's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, CelLBxHealth ranks #107 out of 195 companies for PB Ratio. This places CelLBxHealth in the lower half of its industry. The industry median PB Ratio is 2.03. CelLBxHealth's value of 4.00 is 97% above this benchmark. Historically, CelLBxHealth's own PB Ratio has ranged from 0.18 to 8.60 over the past decade. While the company's 10-year median is 3.76 vs. the industry median of 2.03, CelLBxHealth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.03, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CelLBxHealth's current PB Ratio of 4.00 is 97% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CelLBxHealth and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CelLBxHealth's current PB Ratio is 4.00, which is near median its own 10-year median of 3.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
Based on GuruFocus' analysis, CelLBxHealth (FRA:DWV) is currently considered Possible Value Trap. The stock's GF Value™ is €0.04, compared to a current price of €0.02 — trading 60% below its estimated fair value. The current PB Ratio is 4.00, which is near median its 10-year median of 3.76 and 97% above the Medical Diagnostics & Research industry median of 2.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current PB Ratio is 4.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DWV has been successfully added to your 
